Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07053800 · ClinicalTrials.gov registry record · Phase 2
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
A Phase 2 study, sponsored by Autolus Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT07053800 is a Phase 2 study that is actively recruiting participants, run by Autolus Limited. The registered enrollment target is 35 participants.
The verdict
NCT07053800, a Phase 2 study, is actively recruiting participants, sponsored by Autolus Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).
Interventions
- BIOLOGICAL Obecabtagene autoleucel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07053800
The ClinicalTrials.gov registry entry for NCT07053800 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Autolus Limited, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Obecabtagene autoleucel is the first listed.
NCT07053800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07053800 about?
NCT07053800 is a clinical study titled "Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)". The purpose of this trial is to evaluate the efficacy and safety of obecabtagene autoleucel (obe-cel) administered once following lymphodepletion in participants with severe, refractory systemic lupus erythematosus (SLE) and active lupus nephritis (LN).
What is the current status of trial NCT07053800?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2026-01-16. Estimated completion is 2029-10.
What interventions are being tested in trial NCT07053800?
The interventions under investigation include: Obecabtagene autoleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT07053800?
This trial is sponsored by Autolus Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.